1. Scrip
  2. >>Business
  3. >>Strategy

GSK Revamps Sales Reps Incentives To Be Competitive In Cancer

 
• By Kevin Grogan

Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.

Carrott
GSK Offers Fresh Incentives To Oncology Field Force • Source: Shutterstock

GlaxoSmithKline PLC is relaxing its strict rules on bonuses for some sales representatives as it looks to attract and retain the best field force talent, especially in oncology.

The UK major introduced a sales force incentive (SFI) program in 2012 that involved scrapping performance-related pay in the wake...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.